News and Trends 2 Mar 2017
There’s a New Record in Biotech Fundraising: Should We Believe the Hype?
Illumina’s cancer diagnostics baby, GRAIL, has raked in a jaw-dropping $1B in Series B. Should Europe get on America’s level? A new genome sequencing company spun out of Illumina, GRAIL, has raised over $900M in a Series B fundraising round. That’s far and away the largest round ever; further, that’s more than most companies hope to be worth, […]